Impact of hepatitis B core antibody (anti HBc) seropositivity on interferon/ribavirin treatment response in patients with chronic hepatitis C.
AntiHBc seropositivity among patients with chronic HCV infection is not a rare entity (57.14 %). We observed that antiHBc antibody seropositivity does not have a significant impact on treatment responses to interferon/ribavirin therapy in patients for chronic HCV infection in contrast to some reports in the literature (Tab. 6, Ref. 39) Full Text (Free, PDF) www.bmj.sk.
Biyikoglu
Ibrahim
I
Department of Gastroenterology, Ankara Education and Research Hospital, Ankara, Turkey.
Filik
Levent
L
Oguz
Dilek
D
Cicek
Bahattin
B
Yilmaz
Birhan
B
Altiparmak
Emin
E
D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage*
D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin